Silexion Therapeutics Corp - IPO
Silexion Therapeutics Corp is set to conduct an initial public offering with a total offering size of up to $13,170,000 of ordinary shares through H.C. Wainwright as the sales agent.
Why this matters
Silexion Therapeutics Corp, a company operating in the biological products sector, is focused on developing innovative therapies, though specific details about its products or target markets are not provided in the filing. The company is coming to market with an initial public offering, aiming to raise up to $13,170,000 through the sale of ordinary shares, with H.C. Wainwright acting as the sales agent. The filing does not specify a particular reason for the timing of the IPO, but the proceeds from the offering will be available for immediate use by the company to implement its business plan.